PMID- 17483070
OWN - NLM
STAT- MEDLINE
DCOM- 20070806
LR  - 20181113
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 85
IP  - 4
DP  - 2007 May
TI  - Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a 
      critical review.
PG  - 287-93
AB  - Intravenous immunoglobulin (IVIG) therapy has been used for autoimmune diseases 
      and disorders involving autoantibodies, including coagulation inhibitors. In this 
      review, we have evaluated the efficacy and safety of IVIG therapy for acquired 
      coagulation inhibitors, including factor VIII inhibitor, and for acquired von 
      Willebrand syndrome on the basis of 44 reports published between 1965 and 2005. 
      Among 35 patients with factor VIII inhibitor, we estimated the efficacy of IVIG 
      therapy alone (which includes complete remissions and partial responses with a 
      clinical benefit) to be 30% (11 cases), whereas the response to combination 
      therapy with IVIG plus immunosuppressive agents (eg, corticosteroid, 
      cyclophosphamide) seemed to be better (approximately 70%, 33/45 cases) than with 
      IVIG therapy alone. In acquired von Willebrand syndrome, the efficacy of IVIG 
      therapy was estimated to be 30%. The response to IVIG therapy appears to occur 
      rapidly, and coagulation inhibitors seem to be neutralized immediately. Moreover, 
      severe complications or side effects rarely occur during IVIG treatment. IVIG 
      therapy thus may be considered one choice for treating acquired coagulation 
      inhibitors, although its efficacy improves when used in combination with 
      immunosuppressive agents.
FAU - Yamamoto, Koji
AU  - Yamamoto K
AD  - Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. 
      kojiy@med.nagoya-u.ac.jp
FAU - Takamatsu, Junki
AU  - Takamatsu J
FAU - Saito, Hidehiko
AU  - Saito H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Blood Coagulation Factor Inhibitors)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Autoimmune Diseases/*drug therapy/immunology
MH  - *Blood Coagulation Factor Inhibitors/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/adverse effects/*therapeutic use
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Syndrome
MH  - von Willebrand Diseases/*drug therapy/immunology
RF  - 72
EDAT- 2007/05/08 09:00
MHDA- 2007/08/07 09:00
CRDT- 2007/05/08 09:00
PHST- 2007/05/08 09:00 [pubmed]
PHST- 2007/08/07 09:00 [medline]
PHST- 2007/05/08 09:00 [entrez]
AID - 36R1W428T42M5681 [pii]
AID - 10.1532/IJH97.06222 [doi]
PST - ppublish
SO  - Int J Hematol. 2007 May;85(4):287-93. doi: 10.1532/IJH97.06222.